TRIM16 has recently been identified as a novel suppressor of pathological cardiac hypertrophy, acting through interaction with Prdx1 to inhibit its phosphorylation and thereby activate the Nrf2 pathway, ultimately attenuating cardiomyocyte enlargement and adverse remodeling [247]. The gene discussed is TRIM16; the disease is cardiac hypertrophy.